Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.48 EPS

Analysts expect that Axovant Sciences Ltd (NASDAQ:AXON) will announce earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Axovant Sciences’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.25). Axovant Sciences also reported earnings per share of ($0.48) during the same quarter last year. The company is expected to issue its next earnings results on Tuesday, February 20th.

According to Zacks, analysts expect that Axovant Sciences will report full year earnings of ($2.18) per share for the current fiscal year, with EPS estimates ranging from ($2.32) to ($2.03). For the next fiscal year, analysts forecast that the company will report earnings of ($1.79) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Axovant Sciences.

A number of research analysts have weighed in on the stock. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a research report on Tuesday. Cowen reissued a “hold” rating on shares of Axovant Sciences in a research report on Tuesday. Zacks Investment Research lowered shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Chardan Capital raised shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price for the company in a research report on Wednesday, January 10th. Finally, ValuEngine raised shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $13.61.

Axovant Sciences (NASDAQ AXON) traded down $0.01 during trading on Friday, reaching $1.68. 764,989 shares of the company’s stock were exchanged, compared to its average volume of 1,467,584. The firm has a market cap of $181.62, a price-to-earnings ratio of -0.73 and a beta of -0.97. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.94 and a current ratio of 4.58. Axovant Sciences has a 52-week low of $1.47 and a 52-week high of $27.98.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN increased its stake in Axovant Sciences by 1.6% in the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after acquiring an additional 355 shares during the period. The Manufacturers Life Insurance Company increased its stake in Axovant Sciences by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after acquiring an additional 3,184 shares during the period. California State Teachers Retirement System increased its stake in Axovant Sciences by 10.0% in the second quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after acquiring an additional 4,800 shares during the period. New York State Common Retirement Fund increased its stake in Axovant Sciences by 27.5% in the second quarter. New York State Common Retirement Fund now owns 32,000 shares of the biotechnology company’s stock valued at $742,000 after acquiring an additional 6,899 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Axovant Sciences by 24.7% in the second quarter. Alliancebernstein L.P. now owns 52,000 shares of the biotechnology company’s stock valued at $1,206,000 after acquiring an additional 10,300 shares during the period. 96.82% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/02/17/brokerages-expect-axovant-sciences-ltd-axon-to-post-0-48-eps.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply